Trial Profile

Randomized Phase II Trial of Chemotherapy of Physician's Choice Plus Trastuzumab Versus Chemotherapy of Physician's Choice Plus Trastuzumab Plus Pertuzumab In Women With Pretreated, HER2-Overexpressing Metastatic Breast Cancer (MBC)

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 05 Dec 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Pertuzumab (Primary) ; Capecitabine; Docetaxel; Paclitaxel; Trastuzumab; Vinorelbine
Indications Advanced breast cancer; HER2 positive breast cancer
Focus Therapeutic Use
Sponsors US Oncology Research

29 Nov 2022 Status changed from active, no longer recruiting to discontinued.
03 Dec 2021 Planned End Date changed from 31 Dec 2020 to 1 Jun 2022.
03 Dec 2021 Planned primary completion date changed from 31 Dec 2019 to 1 Jun 2022.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com